Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disord... Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. 詳細を表示
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc...
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ:...
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 7.51 | 24.2492734905 | 30.97 | 38.486 | 29.105 | 61376 | 34.87549085 | CS |
4 | -1.91 | -4.72889329042 | 40.39 | 41.5 | 28.21 | 76353 | 34.72811328 | CS |
12 | -0.49 | -1.25737746985 | 38.97 | 49.46 | 28.21 | 115485 | 38.49670042 | CS |
26 | 37.3888 | 3426.39296188 | 1.0912 | 79.02 | 0.94 | 1595575 | 34.87695759 | CS |
52 | 36.35 | 1706.57276995 | 2.13 | 79.02 | 0.93 | 809026 | 34.41079367 | CS |
156 | 26.58 | 223.361344538 | 11.9 | 79.02 | 0.93 | 1489477 | 14.53826912 | CS |
260 | -6.27 | -14.0111731844 | 44.75 | 79.02 | 0.93 | 1388527 | 14.68483369 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約